Back to search results
NCT06578429

Deep TMS of Neural Circuits Associated With Stimulant Use Disorder

Recruiting
NAAges 25–75InterventionalTreatment
Stanford University
~30 participants
Updated 2025-09-12 on ClinicalTrials.gov
What's tested:Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - ActiveDeep Transcranial Magnetic Stimulation (dTMS) H4 coil - Sham

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Insula Function
Measured over 1-4 days post-treatment
+1 more outcome measured

Conditions

Methamphetamine Use Disorder
Transcranial Magnetic Stimulation

NCT06578429

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • VA Palo Alto Health Care System

    Palo Alto, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Claudia B Padula, PhD · PRINCIPAL_INVESTIGATOR · Stanford University
  • Michelle R Madore, PhD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Samantha Ward, BS
[email protected]
650-493-5000 · ext. 63840
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, ferromagnetic metal in the head and body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device/object in the head and body within 30 cm of the treatment coil.
General medical condition, disease, or neurological disorder that interferes with the assessments or participation.
Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk.
Current substance abuse as determined by positive toxicology screen
Have a mass lesion, cerebral infarct, or other active CNS disease, including a seizure disorder.
A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study.
Severe impediment to vision, hearing and/or hand movement, as this is likely to interfere with the ability to follow study protocols.
Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness).
Taking benzodiazepines or neuroleptic medications, or any medication known to alter seizure threshold.
Acute or unstable chronic illness.
Current or lifetime history of bipolar disorder or psychosis.
Participation in another concurrent intervention-based clinical trial.

What this trial measures

  • Insula Function1-4 days post-treatment

    The primary measure of SN function will include insula activation during the monetary incentive delay task, anticipation of loss contrasted with no loss

  • Percentage of Days Abstinent3 months post-treatment

    Methamphetamine use outcomes will be assessed using the TimeLine Follow Back (TLFB) Method, which utilizes calendar cue to recall recent, self-reported substance use, combined with objective biomarker data